Prothena's PRX002, a preclinical treatment targeting Parkinson's disease, is at the heart of a deal with Swiss pharma giant Roche, worth up to $600 million plus 30% of U.S. profits to the Irish biotech.
A new study out of UCLA points to a potential biomarker for identifying which patients have the "fast" form of the disease and will need significant help early on.
Spotting early-stage Parkinson's disease is a major goal, because it could be key to developing treatments that stop, or at least slow its progression. But where can you reliably find the best biomarker to accomplish this? It might be just under the skin, researchers from Beth Israel Deaconess Medical Center have concluded.
Parkinson's disease is bad enough, but when it also involves dementia the condition is particularly difficult. A recent study published online in PLoS ONE suggests that lipids involved in ceramide metabolism may serve as a biomarker for people with Parkinson's who are at increased risk for mild cognitive impairment.
Civitas Therapeutics picked up $38 million in second-round financing to finish a Phase IIb trial and begin Phase III for its ARCUS respiratory delivery platform to treat Parkinson's disease.
The degree of neuroinflammation was significantly associated with more severe depression, fatigue and cognitive impairment even after taking into consideration other factors, such as age, gender and disease duration.
A research team has developed a Parkinson's biomarker diagnostic test that is showing promise on its own and fueling momentum in a broader effort to tackle the disease and figure out what makes it tick.
In another setback for Chelsea Therapeutics, drug regulators have identified certain technical deficiencies for the biotech's lead investigational therapeutic Northera (droxidopa) in a review of the company's resubmitted New Drug Application.
Researchers at the University of Alabama are investigating whether a reduced sense of smell, or hyposmia, could be used as a biomarker to help detect Parkinson's disease.
Having failed so far to get its extended-release Parkinson's drug Rytary to market, Impax Laboratories ($IPXL) is turning to asking three big-name specialists what it should do.